4,651
Views
31
CrossRef citations to date
0
Altmetric
Position Paper

Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016

, , , &

References

  • Marsh K, Lanitis T, Neasham D, et al. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. PharmacoEconomics. 2014;32:1–10.
  • McKenna C, Soares M, Claxton K, et al. Unifying research and reimbursement decisions: case studies demonstrating the sequence of assessment and judgments required. Value Health. 2015;18:865–875.
  • Aitken M. Impact of cost-per QALY reimbursement criteria on access to cancer drugs (pp. 1–33). IMS Institute for Healthcare Informatics; 2014.
  • Devlin N, Ijzerman M, Marsh K, et al. MCDA for healthcare decision making – an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.
  • Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012 Dec;15(8):1172–1181.
  • Marsh K, Caro J, Muszbek N. Does the future belong to MCDA? ISPOR CONNECTIONS; 2012 . Available from: https://www.ispor.org/news/articles/Nov-Dec12/DoestheFutureBelongtoMCDA.asp
  • Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006 cited 2015 Oct 14;4:14. PMC.
  • Thokala P, Devlin N, Marsh K, et al. MCDA for healthcare decisions- emerging good practices: report 2 of the ISPOR MCDA task force DRAFT. ISPOR 4th Latin America Conference Educational Symposia. 12 September 2013, Buenos Aires, Argentina; 2015.
  • Golan O, Hansen P, Kaplan G, et al. Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights? Health Policy. 2011 Oct;102(2–3):126–135.
  • Endrei D, Molics B, Agoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17:487–489.
  • Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013 Dec;16(8):1163–1169.
  • Toumi M. MCDA utiliztion for public health decision process. ISPOR LA Buenos Aires: London; 2013.
  • Devlin N, Sussex J. Incorporating multi criteria in HTA: methods and process. London: Office of Health Economics; 2011 Mar.
  • Adams B, Megget K, Bowie C, et al. Orphan drugs, raw deal? PharmaTimes Magazine. 2013. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402125/.
  • Airoldi M, Morton A, Smith JAE, et al. STAR--people-powered prioritization: a 21st-century solution to allocation headaches. Med Decis Mak. 2014 Nov;34(8):965–975.
  • Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in healthcare: a systematic review and bibliometric analysis. Health Expect. 2014;18:1894–1905.
  • Guest J, Harrop JS, Aarabi B, et al. Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network. J Neurosurg Spine. 2012;17(Suppl1):94–101.
  • Diaby V, Goeree R, Hoch J, et al. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):13–19.
  • Tony M, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011 Nov 30;11:329.
  • Danner M, Hummel JM, Volz F, et al. Integrating patients’ views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Healthcare. 2011 Oct;27(4):369–375.
  • Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Sao Paulo, Brazil: World Health Organization Regional Office for Europe; 2015.
  • Deans M, De Rosch M, Voisin E Regulatory approval and market access: a winning combination for drug launch optimization. 2014 Oct. Available from: www.scriptsregulatorsaffairs.com
  • Borg P, Fogelholm M. Stakeholder appraisal of policy options for responding to obesity in Finland. Obes Rev. 2007;8 Suppl 2(Suppl2):47–52.
  • Van Til JA. Integrating preferences into decision making: the treatment of ankle-food impairment in stroke. Enschede: Twente University; 2009.
  • Baeten SA, Baltussen RMPM, Uyl-De Groot CA, et al. Incorporating equity-efficiency interactions in cost-effectiveness analysis: three approaches applied to breast cancer control. Value Health. 2010;13(5):573–579.
  • Radaelli G, Lettieri E, Masella C, et al. Implementation of eunethta core model® in Lombardia: the VTS framework. Int J Technol Assess Healthc. 2014 Jan;30(1):105–112.
  • Defechereux T, Paolucci F, Mirelman A, et al. Healthcare priority setting in Norway a multicriteria decision analysis. BMC Health Serv Res. 2012;12:39–45.
  • Kanters TA, Hakkaart L, Rutten-Van Mölken MP, et al. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug? Expert Rev Pharmacoeconomics Outcomes Res. 2015;15(4):557–559.
  • Hansen P, Hendry A, Naden R, et al. A new process for creating points systems for prioritising patients for elective health services. Clin Gov Int J. 2012;17:200–209.
  • Miot J, Wagner M, Khoury H, et al. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Eff Resour Alloc. 2012 Feb 29;10(1):2.
  • Jehu-Appiah C, Baltussen R, Acquah C, et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value Health. 2008;11(7):1081–1087.
  • Youngkong S, Baltussen R, Tantivess S, et al. Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand. Value Health. 2012 Sep–Oct;15(6):961–970.
  • Brito A, Fagundes M, Nunes O, et al. Proposra para Incorporacao de medicamentos em Doencas Raras: definicao de Criterios para Avaliacao de Reembolso de Medicamentos Orfaos para Tratamento de Doencas Raras no SUS. Interfarma: Chile; 2015.
  • Nobre FF, Trotta LTF, Gomes LFAM. Multi-Criteria decision making: an approach to setting priorities in healthcare. Stat Med. 1999;18(23):3345–3354.
  • Pichon-Riviere A. IP3: “Planes de Beneficios en salud en Latinoamerica: cúal es el Estado Actual y Cúales son los Desafios Futuros”. ISPOR LA Chile: Santiago de Chile; 2015.
  • Jaramillo HEC Uso de Analysis de Decision Multi-Criterio Para Priorizar en Colombia. IETS.ORG.COM. 2013.
  • Informe de Evaluacíon. Licitacíon Publíca Para la Adquisicion de Infliximab 100MG Para el Hospital Clinco de la Universidad de Chile. Chile: Informe de Evaluacíon; 2014.
  • Espinoza MA. Análisis de Decisiones Multicrietrios. Es la mejor manera de conducir decisiones en Latinoamerica. ISPOR LA Chile; BMC Health Services Research - Springer; 2015
  • Sotomayor R, Sanchez X, Armijos L Health technology assessment in Ecuador. Health Policy In Latin America, ISPOR Latin American Consortium News Across Latin America. 2015 Feb/Mar;3(1).
  • Omelyanovsky V, Fedyaeva V, Rebrova O. Application of multi-criteria decision analysis in Russian healthcare. Health Policy. 2015 Mar/Apr.